5,000 plus new medicines in the R&D pipeline: when we talk about "Research, Progress, Hope," that's what we mean.
When President Clinton was first inaugurated in 1993, HIV/AIDS was continuing its inexorable devastation in the U.S. with 14 deaths per 100,000 patients. This would climb to 16 deaths per 100,000 in 1995. By the time President Clinton started his second term in 1997, the rate had dropped dramatically to only 6 deaths per 100,000 patients.
In New York City in 1916, in the first large outbreak of polio, more than 9000 people were infected and more than 2300 people died. The nationwide toll was nearly triple. As the years passed, the death toll mounted. A record number of cases were seen in the U.S.
[caption id="attachment_5497" align="alignleft" width="150" caption="Woodrow Wilson Sworn in as President"][/caption]
In the last few weeks there has been much written about the need to ensure appropriate clinical trials in India. Today, Jay Taylor, Vice President of International at PhRMA published an article on this subject on Apothecurry, an influential health site in India.
Come and take a journey with us on Pinterest and the Catalyst all this week as we showcase the last century of major medical innovation milestones around presidential inaugural years.
Over the last year, I have read in various publications that the biopharmaceutical pipeline is drying up and the industry I represent isn't as innovative as it used to be.
My response has always been simple: This couldn't be further from the truth.
In the interest of public radio parlance and fair and balanced journalism, I'd like to suggest a new opening sentence to NPR's story on physician prescribing decisions and generic drug utilization: "We're living in the golden age of generic drugs - made possible by innovative biopharma
In the interest of public radio parlance and fair and balanced journalism, I’d like to suggest a new opening sentence to NPR’s story on physician prescribing decisions and generic drug utilization:
“We’re living in the golden age of generic drugs – made possible by innovative biopharmaceutical research companies.”
You've likely seen the good news that the U.S. Food and Drug Administration (FDA) approved 39 New Molecular Entities (NMEs) in 2012, the highest number in 16 years.
The start of the year is always a time to think about both what can be accomplished as well as the challenges ahead. That's what PhRMA president & CEO John Castellani does in the most recent issues of Chain Drug Review.
The search for a HIV/AIDS vaccine goes on. Word of a possible breakthrough last week is encouraging.